Prevention of perinatal hepatitis B virus transmission by combined passive–active immunoprophylaxis in Iwate, Japan (1981–1992) and epidemiological evidence for its efficacy

Koyama, Tomiko; Matsuda, Isao; Sato, Shunichi; Yamada, Hiroshi

doi:10.1016/s1386-6346(03)00168-2

Cited by 41 publications

(51 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Transmission of HBV for establishing the persistent carrier state has been prevented effectively by the national program for passive and active immunoprophylaxis of perinatal transmission of HBV from carrier mothers to their babies implemented in 1986 in Japan [3,4]. Unlike HBV infection that tends to perpetuate in the infancy but resolves spontaneously in most cases of adulthood infection, infection with HCV in adults has a high propensity to become persistent (70-80%) [5,6].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sex- and Age-Specific Carriers of Hepatitis B and C Viruses in Japan Estimated by the Prevalence in the 3,485,648 First-Time Blood Donors during 1995–2000

et al. 2004

View full text Add to dashboard Cite

Objective: Carriers of hepatitis B virus (HBV) and hepatitis C virus (HCV) in Japan were estimated on a national basis. Methods: Sera from the first-time blood donors aged 16–64 years in eight jurisdictions of the Japanese Red Cross Blood Center during 1995–2000 were tested for hepatitis B surface antigen (HBsAg) and antibody to HCV (anti-HCV). Viremia with HCV was estimated to be present in 70% of donors with anti-HCV. Results: HBsAg was detected in 22,018 of 3,485,648 (0.63%) blood donors including 12,990 of 1,780,149 (0.73%) men and 9,028 of 1,705,499 (0.53%) women, and anti-HCV in 17,010 (0.49%) including 8,504 (0.48%) men and 8,506 (0.50%) women. Multiplying the carrier rate by the population registered in the Census 2000, the total HBV carriers aged 15–65 years were estimated at 967,753 (95% confidence interval 806,760–1,128,745), of whom 571,210 (479,267–663,152) were men and 396,543 (327,494–465,593) were women. Likewise, the total HCV carriers were estimated at 884,954 (95% confidence interval 725,082–1,044,826), of whom 464,363 (377,927–550,799) were men and 420,591 (347,156–494,027) were women. Conclusion: Estimated numbers of HBV and HCV carriers would help plan to prevent the development of hepatocellular carcinoma in Japan.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Anti-HCV was determined by passive hemagglutination with commercial kits [the second generation HCV PHA (Dinabott, Tokyo, Japan) and HCV PA (Ortho Diagnostics, Tokyo, Japan)]. The cutoff level for the hemagglutination test for HBsAg was 2 2 and that for anti-HCV was either 2 5 or 2 4 .…”

Section: Serum Markers For Hepatitis Virus Infectionsmentioning

confidence: 99%

Sex- and Age-Specific Carriers of Hepatitis B and C Viruses in Japan Estimated by the Prevalence in the 3,485,648 First-Time Blood Donors during 1995–2000

et al. 2004

View full text Add to dashboard Cite

show abstract

“…In Shizuoka, Japan, 494 babies born to HBV carrier mothers received the preventative vaccination during the period of 1986-1994, and 462 (93.5%) were protected [8]. After the prevention program was introduced, HBV carrier rates in the pediatric population in Iwate had decreased from 0.8% in 1985 to 0.04% in 2005 [3]. This effect has been confirmed by an analysis of first time blood donors among the teenaged Japanese population [9].…”

Section: Discussionmentioning

confidence: 89%

“…A high-risk approach for treatment of this group of infants utilizing HBV vaccines has been adopted in a few countries, including, England, the Scandinavian countries and Japan [3,7]. A prevention program against maternal HBV infection for a selected population was introduced in Japan in January of 1986.…”

Section: Discussionmentioning

confidence: 99%

“…In Japan, a nationwide prevention program utilizing passive-active immunoprophylaxis for high-risk infants against maternal HBV transmission was introduced in January of 1986 [3]; most other countries have introduced universal HBV vaccination programs. In the high-risk program, babies born to HBV carrier mothers received two doses of hepatitis B immune globulins (HBIG), one at birth and the second at 2 months, and HBV vaccine at 2, 3 and 5 months after birth.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers

Tajiri

Tanaka

Brooks

et al. 2010

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

Natural history of compensated cirrhosis in the Child-Pugh class a compared between 490 patients with hepatitis C and 167 with B virus infections

et al. 2006

View full text Add to dashboard Cite

Natural histories of compensated cirrhosis in the Child-Pugh class A were compared between the 490 patients infected with hepatitis C virus (HCV) and 167 patients with hepatitis B virus (HBV) who were followed for more than 1 year up to 20 years without antiviral treatment. Patients with HCV were older (median age: 59 vs. 45 years), less predominantly male (59.0% vs. 76.0%), transfused more frequently (49.2% vs. 9.0%), and had higher aminotransferase as well as lower albumin levels and fewer platelets (P < 0.001 for all). Death was commoner (55.1% vs. 35.9%, P < 0.001) and hepatocellular carcinoma developed more often (53.9% vs. 28.7%, P < 0.001) in patients with HCV than HBV. In multivariate analysis, low albumin levels (hazard ratio: 1.65), alpha-fetoprotein (1.55), alcohol consumption (1.49), age >55 years (1.47), and retention of indocyanine green (1.39) were independent risk factors for the survival in patients with HCV, while male gender (4.43), age >45 years (2.24), retention of indocyanine green (2.14), hepatitis B e antigen (2.11), and low platelet counts (1.91) were in those with HBV. Chances for survival was significantly different (P < 0.001) among patients with HCV having low (number of factors: 0-1), medium (2-3), and high risks (4-5), as well as in those with HBV having low (0-1), medium (2-4), and high risks (5-6). In conclusion, survival and development of hepatocellular carcinoma, and factors for survival, are considerably different between patients with compensated cirrhosis infected with HCV and HBV, which would need to be taken into consideration in their management and planning treatment strategies.

show abstract

Prevention of perinatal hepatitis B virus transmission by combined passive–active immunoprophylaxis in Iwate, Japan (1981–1992) and epidemiological evidence for its efficacy

Cited by 41 publications

References 21 publications

Sex- and Age-Specific Carriers of Hepatitis B and C Viruses in Japan Estimated by the Prevalence in the 3,485,648 First-Time Blood Donors during 1995–2000

Sex- and Age-Specific Carriers of Hepatitis B and C Viruses in Japan Estimated by the Prevalence in the 3,485,648 First-Time Blood Donors during 1995–2000

Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers

Natural history of compensated cirrhosis in the Child-Pugh class a compared between 490 patients with hepatitis C and 167 with B virus infections

Contact Info

Product

Resources

About